Cerus Co. (NASDAQ:CERS) Shares Acquired by Ieq Capital LLC

Ieq Capital LLC lifted its holdings in shares of Cerus Co. (NASDAQ:CERSFree Report) by 1.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,169,487 shares of the biotechnology company’s stock after buying an additional 26,748 shares during the period. Ieq Capital LLC’s holdings in Cerus were worth $3,341,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in CERS. R Squared Ltd acquired a new stake in Cerus in the fourth quarter valued at about $29,000. Creative Planning lifted its position in Cerus by 51.3% in the third quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 8,411 shares during the period. PCA Investment Advisory Services Inc. acquired a new stake in Cerus in the fourth quarter valued at about $46,000. Intech Investment Management LLC acquired a new stake in Cerus in the third quarter valued at about $71,000. Finally, SG Americas Securities LLC acquired a new stake in Cerus in the third quarter valued at about $121,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Cerus Trading Down 5.2 %

Shares of Cerus stock opened at $1.65 on Friday. Cerus Co. has a 12-month low of $1.38 and a 12-month high of $2.59. The company has a current ratio of 2.59, a quick ratio of 1.92 and a debt-to-equity ratio of 1.19. The stock has a market cap of $306.42 million, a PE ratio of -15.00 and a beta of 1.29. The company has a 50-day moving average of $1.74 and a two-hundred day moving average of $1.83.

Cerus (NASDAQ:CERSGet Free Report) last issued its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.01). Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. The company had revenue of $50.81 million during the quarter, compared to analysts’ expectations of $50.81 million. On average, research analysts anticipate that Cerus Co. will post -0.08 EPS for the current fiscal year.

Insider Buying and Selling at Cerus

In other Cerus news, Director Eric Bjerkholt sold 20,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $1.78, for a total value of $35,600.00. Following the completion of the transaction, the director now directly owns 162,133 shares of the company’s stock, valued at approximately $288,596.74. This trade represents a 10.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 3.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $4.00 price objective on shares of Cerus in a research report on Friday.

Get Our Latest Stock Analysis on Cerus

Cerus Profile

(Free Report)

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

See Also

Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Co. (NASDAQ:CERSFree Report).

Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.